Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that data from its Phase 2 clinical study of sotagliflozin in type 1 diabetes will be presented in oral …
Wedbush analyst Liana Moussatos was out pounding the table on Lexicon Pharmaceuticals, Inc. (NYSE:LXRX) Thursday, reiterating an Outperform rating and price target of $19, which …
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares have taken off, adding more than 60% to trade at $13.
Seadrill Ltd (NYSE:SDRL) fell -2.13% in pre-market trading down to $8.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat …
Wedbush’s healthcare analyst Liana Moussatos came out with a research note on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), after the company reported its fourth-quarter results and provided update on its pipeline.
In a research report released yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target, …
In a research report published yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target …
